Loading
A phase 1/2 trial of Repotrectinib in non-Hodgkin lymphoma and brain and spinal cord tumours, run by Turning Point Therapeutics, Inc., now recruiting.
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations is a phase 1/2 interventional study registered as NCT04094610 by Turning Point Therapeutics, Inc., with 75 participants planned, started 2020-03-12 and due to reach its primary completion in 2026-09-30. Interventions recorded: Oral repotrectinib (TPX-0005).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Repotrectinib, Bristol Myers Squibb, Small-molecule kinase inhibitors and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Small-molecule kinase inhibitors and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Small-molecule kinase inhibitors and the tag pipeline.
Shares Repotrectinib, Bristol Myers Squibb, Small-molecule kinase inhibitors and the tag pipeline.
Shares Bristol Myers Squibb and the tag pipeline.
Shares Bristol Myers Squibb and the tag pipeline.
Shares Bristol Myers Squibb and the tag pipeline.
Shares Bristol Myers Squibb, Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/